Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Caplin Steriles Gets 10 FDA Observations; Its Response Now Takes Center Stage

The U.S. Food and Drug Administration completed an unannounced inspection of Caplin Steriles’ injectable and ophthalmic manufacturing facility in Gummidipoondi, Tamil Nadu, on August 21, 2026. The inspection ended with a Form 483 containing 10 observations. Caplin Point Laboratories said
  • News
Caplin Steriles Gets 10 FDA Observations; Its Response Now Takes Center Stage

NATCO Calls 4 FDA Observations Procedural; Response Quality Now Matters Most

NATCO Pharma’s finished dosage formulations facility in Parawada, Visakhapatnam, received a U.S. FDA Form 483 with four observations after an inspection conducted from August 17 to 21, 2026. NATCO described the observations as procedural and said it expects to address
  • News
NATCO Calls 4 FDA Observations Procedural; Response Quality Now Matters Most

QMS Implementation in 2026: GMP Compliance Failures and Regulatory Inspection Risks

This article explains how QMS Implementation in 2026 strengthens GMP inspection readiness by improving CAPA effectiveness, data integrity compliance, and change control management. It also highlights how pharmaceutical quality systems reduce FDA inspection findings and ensure regulatory compliance stability across
  • Blog, Quality Management System
Pharmaceutical quality system model showing CAPA effectiveness, data integrity compliance, and change control management aligned with GMP inspection readiness and ICH Q10 principles